Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company's Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX
PR NewswireJun 5, 2023
SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- Gencurix (KOSDAQ #229000), a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly comparing the accuracy of its breast cancer prognostic test, GenesWell BCT, with Oncotype DX, the globally top-selling test, confirming its outstanding performance. The study, presented at the American Society of Clinical Oncology (ASCO), one of the world's top three cancer conferences, on June 4th, attracted s